Exagen Inc (XGN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Exagen Inc (XGN) has a cash flow conversion efficiency ratio of -0.722x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.42 Million) by net assets ($14.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Exagen Inc balance sheet quality to measure how much of total assets are equity-financed.
Exagen Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Exagen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow reinvestment rate of Exagen Inc to assess the company's total reinvestment commitment from operating cash flow.
Exagen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Exagen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Townsquare Media Inc
NYSE:TSQ
|
-0.116x |
|
Whanin Pharm
KO:016580
|
0.006x |
|
Merkur PrivatBank KgaA
XETRA:MBK
|
N/A |
|
Y.C.C. Parts MFG Co Ltd
TW:1339
|
0.041x |
|
Active Biotech AB
ST:ACTI
|
-1.600x |
|
Havila Kystruten AS
OL:HKY
|
-0.034x |
|
Synchronoss Technologies Inc
NASDAQ:SNCR
|
0.711x |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
-0.022x |
Annual Cash Flow Conversion Efficiency for Exagen Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Exagen Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see Exagen Inc market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $17.45 Million | $-13.62 Million | -0.781x | +43.90% |
| 2024-12-31 | $9.54 Million | $-13.28 Million | -1.392x | -118.42% |
| 2023-12-31 | $22.69 Million | $-14.46 Million | -0.637x | +15.82% |
| 2022-12-31 | $42.46 Million | $-32.14 Million | -0.757x | -217.23% |
| 2021-12-31 | $84.94 Million | $-20.27 Million | -0.239x | +29.11% |
| 2020-12-31 | $41.84 Million | $-14.08 Million | -0.337x | -92.94% |
| 2019-12-31 | $55.66 Million | $-9.71 Million | -0.174x | -112.63% |
| 2018-12-31 | $-6.73 Million | $-9.30 Million | 1.381x | -41.59% |
| 2017-12-31 | $-4.64 Million | $-10.97 Million | 2.365x | +340.77% |
| 2015-12-31 | $-22.18 Million | $-11.90 Million | 0.537x | -30.00% |
| 2014-12-31 | $-14.06 Million | $-10.77 Million | 0.766x | +105.04% |
| 2013-12-31 | $451.00K | $-6.87 Million | -15.222x | -881.67% |
| 2012-12-31 | $4.82 Million | $-7.48 Million | -1.551x | -- |
About Exagen Inc
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company's lead test… Read more